title: Liver fat content measured by magnetic resonance spectroscopy at 3.0 tesla independently correlates with plasminogen activator inhibitor-1 and body mass index in type 2 diabetic subjects.
abstract: We measured liver fat content by 3-Tesla magnetic resonance spectroscopy (MRS) in 34 non- to mild obese Japanese subjects with type 2 diabetes, who were not complicated with any liver diseases including clinical fatty liver (liver/spleen ratio of computed tomography [CT] < 0.9) and were not being treated with oral hypoglycemic agents, insulin, or lipid-lowering agents, and analyzed the relationship between liver fat content and body composition and plasma metabolite. The liver fat content is significantly correlated with variables relating to obesity (body mass index [BMI], body weight, fat mass, waist to hip ratio, visceral fat area, subcutaneous fat area, and serum triglyceride), insulin resistance (fasting plasma insulin and homeostasis model assessment of insulin resistance [HOMA-IR]), adipocytokines (serum plasminogen activator inhibitor-1 [PAI-1] and leptin), and serum cholinesterase, but not CT liver/spleen ratio, which is correlated only with fasting plasma glucose, BMI, and HOMA-IR. Multiple regression analysis revealed that the liver fat content is independently associated with serum PAI-1 level (p < 0.001) and BMI (p < 0.05), but not visceral fat area. MRS is a more sensitive method for quantifying liver fat content than CT in type 2 diabetic subjects with non- to mild obesity and without clinical fatty liver.
authors.affiliation: Department of Diabetes and Metabolism, Iwate Medical University, Morioka, Japan. hozisik@inonu.edu.tr
authors.forename: Mototsugu
authors.initials: M
authors.lastname: Ishii
authors.forename: Yoshichika
authors.initials: Y
authors.lastname: Yoshioka
authors.forename: Wataru
authors.initials: W
authors.lastname: Ishida
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Kaneko
authors.forename: Fumikado
authors.initials: F
authors.lastname: Fujiwara
authors.forename: Haruhito
authors.initials: H
authors.lastname: Taneichi
authors.forename: Masanori
authors.initials: M
authors.lastname: Miura
authors.forename: Makiko
authors.initials: M
authors.lastname: Toshihiro
authors.forename: Noriko
authors.initials: N
authors.lastname: Takebe
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Iwai
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Suzuki
authors.forename: Jo
authors.initials: J
authors.lastname: Satoh
mesh_terms: D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D005260:Female; D006801:Humans; D050356:Lipid Metabolism; D008055:Lipids / Q000032:analysis; D008099:Liver / Q000378:metabolism*; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D012044:Regression Analysis
chemical_list: D008055:Lipids; D017395:Plasminogen Activator Inhibitor 1